Apixaban reduced VTE and did not increase major bleeding compared with enoxaparin in hip replacement

ACP Journal Club17 May 2011Apixaban reduced VTE and did not increase major bleeding compared with enoxaparin in hip replacementJames Douketis, MDJames Douketis, MDSt. Joseph’s Hospital, Hamilton, Ontario, Canada (J.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-10-201105170-02007 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationLassen MR, Gallus A, Raskob GE, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487-98. https://pubmed.ncbi.nlm.nih.gov/21175312Clinical Impact RatingsHematology: References1 Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PMID: 8707165] Google Scholar2 Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22. [PMID: 19071881] Google Scholar3 Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:454S-545S. [PMID: 18574272] Google Scholar4 Lassen MR, Raskob GE, Gallus A, et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604. [PMID: 19657123] Google Scholar5 Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des. 2010;16:3436-41. [PMID: 20858185] Google Scholar Author, Article, and Disclosure InformationAuthors: James Douketis, MDAffiliations: St. Joseph’s Hospital, Hamilton, Ontario, Canada (J.D.)This article was published at Annals.org on 3 May 2011. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRivaroxaban was noninferior to enoxaparin for preventing short-term recurrent VTE and superior to placebo in continued treatment James Douketis Metrics 17 May 2011Volume 154, Issue 10Page: JC5-7KeywordsAnticoagulantsApixabanDeep vein thrombosisHemorrhageHipPulmonary embolismSafetySurgeryTotal hip replacementVenous thromboembolism ePublished: 17 May 2011 Issue Published: 17 May 2011 Copyright & PermissionsCopyright © 2011 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...